Bisphosphonate therapy ameliorates hearing loss in mice lacking osteoprotegerin

Journal of Bone and Mineral Research

Volumn 24, Issue 1, 2009, Pages 43-49

  Kanzaki, Sho ^a   Takada, Yasunari ^a   Ogawa, Kaoru ^a   Matsuo, Koichi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Bisphosphonates; Knockout in; Osteoclasts; Osteoprotegerin; Rodent

Indexed keywords

OSTEOPROTEGERIN; RISEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; EVOKED BRAIN STEM AUDITORY RESPONSE; EXPERIMENTAL MOUSE; HEARING LOSS; HISTOLOGY; MICROSCOPY; MOUSE; NONHUMAN; PREVENTION AND CONTROL; TREATMENT DURATION;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; COCHLEA; DIPHOSPHONATES; ETIDRONIC ACID; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; FEMALE; HEARING; HEARING LOSS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OSTEOPROTEGERIN; TIME FACTORS;

EID: 58149089978     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.080812     Document Type: Article

References (36)

1. Seeman E 2008 Bone quality: The material and structural basis of bone strength. J Bone Miner Metab 26:1-8.
2. Frolenkov GI, Belyantseva IA, Friedman TB, Griffith AJ 2004 Genetic insights into the morphogenesis of inner ear hair cells. Nat Rev Genet 5:489-498.
3. Jung JY, Chole RA 2002 Bone resorption in chronic otitis media: The role of the osteoclast. ORL J Otorhinolaryngol Relat Spec 64:95-107.
4. Merchant SN 2004 Ossiculoplasty and tympanoplasty in chronic otitis media. In: Nadol JB, McKenna MJ (eds.) Surgery of the Ear and Temporal Bone, 2nd ed. Lippincott Williams & Wilkins, Baltimore, MD, USA, pp. 305-324.
5. Boumans LJ, Poublon RM 1991 The detrimental effect of aminohydroxypropylidene bisphosphonate (APD) in otospongiosis. Eur Arch Otorhinolaryngol 248:218-221.
6. Kennedy DW, Hoffer ME, Holliday M 1993 The effects of etidronate disodium on progressive hearing loss from otosclerosis. Otolaryngol Head Neck Surg 109:461-467.
7. Yoon TH, Lee SH, Park MH, Chung JW, Kim HJ 2001 Inhibition of cholesteatomatous bone resorption with pamidronate disodium. Acta Otolaryngol 121:178-181.
8. Zehnder AF, Kristiansen AG, Adams JC, Merchant SN, McKenna MJ 2005 Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule. Laryngoscope 115:172-177.
9. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
10. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS 1998 osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268.
11. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H 1998 Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247:610-615.
12. Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka BY, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, Takahashi N 2003 Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144:5441-5449.
13. Kanzaki S, Ito M, Takada Y, Ogawa K, Matsuo K 2006 Resorption of auditory ossicles and hearing loss in mice lacking osteoprotegerin. Bone 39:414-419.
14. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S 2002 Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 347:175-184.
15. Takayanagi H 2005 Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 83:170-179.
16. Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC Jr, Lang R, McClung MR, Mallette LE, Miller PD, Ryan WG, Singer FR, Tucci JR, Eusebio RA, Bekker PJ 1998 Risedronate in the treatment of Paget's disease of bone: An open label, multicenter study. J Bone Miner Res 13:1032-1038.
17. Crandall C 2001 Risedronate: A clinical review. Arch Intern Med 161:353-360.
18. Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, Grauer A, Cahall D, Watts NB 2007 Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:1296-1304.
19. Hahn M, Vogel M, Pompesius-Kempa M, Delling G 1992 Trabecular bone pattern factor-a new parameter for simple quantification of bone microarchitecture. Bone 13:327-330.
20. Anonymous 2003 Buffers and solutions (Appendix 1). In: Nagy A, Gertsenstein M, Vintersten K, Behringer RR (eds.) Manipulating the Mouse Embryo: A Laboratory Manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, USA, pp. 725-734.
21. Probst R 2007 Audiological evaluation of patients with otosclerosis. Adv Otorhinolaryngol 65:119-126.
22. Zhang Z, Zhang X, Avniel WA, Song Y, Jones SM, Jones TA, Fermin C, Chen Y 2003 Malleal processus brevis is dispensable for normal hearing in mice. Dev Dyn 227:69-77.
23. Iurato S, Quaranta A 1999 Malleus-handle fracture: Historical review and three new cases. Am J Otol 20:19-25.
24. Halo N, Okada M, Hakuba N, Hyodo M, Gyo K 2007 Repair of a malleus-handle fracture using calcium phosphate bone cement. Laryngoscope 117:361-363.
25. Kanwi T, Jokay I, Konya J, Szabo LZ, Pytel J, Jori J, Szalmas A, Sziklai I 2006 Detection of osteoprotegerin and TNF-α mRNA in ankylotic stapes footplates in connection with measles virus pnsitivity. Laryngoscope 116:1427-1433.
26. Brookler KH, Tanyeri H 1997 Etidronate for the the neurotologic symptoms of otosclerosis: Preliminary study. Ear Nose Throat J 76:371-376, 379-381.
27. Chole RA, McKenna M 2001 Pathophysiology of otosclerosis. Otol Neurotol 22:249-257.
28. Tau C, Mautalen C, Casco C, Alvarez V, Rubinstein M 2004 Chronic idiopathic hyperphosphatasia: Normalization of bone turnover with cyclical intravenous pamidronate therapy. Bone 35:210-216.
29. Cundy T, Wheadon L, King A 2004 Treatment of idiopathic hyperphosphatasia with intensive bisphosphonatc therapy. J Bone Miner Res 19:703-711.
30. Monsell EM 2004 The mechanism of hearing loss in Paget's disease of bone. Laryngoscope 114:598-606.
31. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF 1994 c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266:443-448.
32. Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ, Wagner EF 2000 Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 24:184-187.
33. Martin TJ, Sims NA 2005 Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11:76-81.
34. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T, Matsuo K 2006 Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 4:111-121.
35. Matsuo K, Irie N 2008 Osteoclast-osteoblast communication. Arch Biochem Biophys 473:201-209.
36. Bonewald LF 2007 Osteocytes as dynamic, multifunctional cells. Ann NY Acad Sci 116:281-290.